Evidence map›Paper›PMID 26263913›Full record

ArticleJournal of lipid research2015

Inhibition of FAAH confers increased stem cell migration via PPARα.

Yvonne Wollank, Robert Ramer, Igor Ivanov, Achim Salamon, Kirsten Peters, Burkhard Hinz

Open access · hybridAbstract read
In one paragraph

Article in Journal of lipid research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Role ofFrontiers in molecular neuroscience · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yvonne WollankInstitute of Toxicology and Pharmacology, Rostock University Medical Center, D-18057 Rostock, Germany Department of Cell Biology, Rostock University Medical Center, D-18057 Rostock, Germany.
Robert RamerInstitute of Toxicology and Pharmacology, Rostock University Medical Center, D-18057 Rostock, Germany.
Igor IvanovInstitute of Toxicology and Pharmacology, Rostock University Medical Center, D-18057 Rostock, Germany.
Achim SalamonDepartment of Cell Biology, Rostock University Medical Center, D-18057 Rostock, Germany.
Kirsten PetersDepartment of Cell Biology, Rostock University Medical Center, D-18057 Rostock, Germany.
Burkhard HinzInstitute of Toxicology and Pharmacology, Rostock University Medical Center, D-18057 Rostock, Germany.
University of Rostock · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Regenerative activity in tissues of mesenchymal origin depends on the migratory potential of mesenchymal stem cells (MSCs). The present study focused on inhibitors of the enzyme fatty acid amide hydrolase (FAAH), which catalyzes the degradation of endocannabinoids (anandamide, 2-arachidonoylglycerol) and endocannabinoid-like substances (N-oleoylethanolamine, N-palmitoylethanolamine). Boyden chamber assays, the FAAH inhibitors, URB597 and arachidonoyl serotonin (AA-5HT), were found to increase the migration of human adipose-derived MSCs. LC-MS analyses revealed increased levels of all four aforementioned FAAH substrates in MSCs incubated with either FAAH inhibitor. Following addition to MSCs, all FAAH substrates mimicked the promigratory action of FAAH inhibitors. Promigratory effects of FAAH inhibitors and substrates were causally linked to activation of p42/44 MAPKs, as well as to cytosol-to-nucleus translocation of the transcription factor, PPARα. Whereas PPARα activation by FAAH inhibitors and substrates became reversed upon inhibition of p42/44 MAPK activation, a blockade of PPARα left p42/44 MAPK phosphorylation unaltered. Collectively, these data demonstrate FAAH inhibitors and substrates to cause p42/44 MAPK phosphorylation, which subsequently activates PPARα to confer increased migration of MSCs. This novel pathway may be involved in regenerative effects of endocannabinoids whose degradation could be a target of pharmacological intervention by FAAH inhibitors.

Indexed as

Adipose TissueAmidesAmidohydrolasesArachidonic AcidsBenzamidesCarbamatesCell MovementCells, CulturedEndocannabinoidsEnzyme InhibitorsEthanolaminesFatty Acid Amide HydrolasesGlyceridesHumansMesenchymal Stem CellsOleic AcidsAmidesAmidohydrolasesanandamideArachidonic AcidsarachidonoylserotoninBenzamidesCarbamatescyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl esterEndocannabinoidsEnzyme InhibitorsEthanolaminesFatty Acid Amide HydrolasesGlyceridesglyceryl 2-arachidonateN-oleoylethanolamineOleic AcidspalmidrolPalmitic AcidsPolyunsaturated AlkamidesPPAR alphaReceptor, Cannabinoid, CB1Serotoninendocannabinoidsfatty acid amide hydrolase inhibitorsmesenchymal stem cellsperoxisome proliferator-activated receptor α

Identifiers

PMID26263913
PMCPMC4583083
OpenAlexW2152935016

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.